Wed, Jul 30, 2014, 3:19 PM EDT - U.S. Markets close in 41 mins.

Recent

% | $
Click the to save as a favorite.

Alnylam Pharmaceuticals, Inc. Message Board

SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • You won't see this stock make any big gains for a long time without money printing courtesy of the FED. Now that the taper is coming to an end, the money flow into the stock market is going to dwindle. Stocks will no products and no earnings are therefore at great risk. This, of course, is the category to which ALNY falls into.

  • Reply to

    Cutting Edge Biotech

    by pmp9409 22 hours ago

    Yes, lots of ifs with this stock. Too many for a stock with a $4B market cap.

    If want to buy something that is under priced and has no "ifs" take a look at PCYC. They've got the best blood cancer drug out there, Imbruvica, fresh with an expanded label by the FDA, and it is a pill that has no side effects to write home about! The folks in Europe are ready to approve it too. The FDA acted three months in advance! Never seen from a government agency. Rituxan is the closest thing to it, an intravenously delivered monoclonal antibody, and it sells about $9B a year. PCYC's market cap is only $9B, which is what Imbruvica's annual sales will be with these quick label expansions by the FDA.

  • The stuff Alnylam and other companies like it are developing are so new there is no way to value the technology. I really think long-term this company may be huge. If they can remain independent, this stock could be a homerun. If....!!!!

    Sentiment: Buy

  • Reply to

    ALN'Y No Drugs for a LONG Time

    by hundleyrandy Jul 20, 2014 7:47 PM

    FDA can be as suspect as they like. It is the trials that will prove or disprove safety, not the FDA. RNAi now on the cutting edge of therapies for most nearly all diseases. Medicine as we know it is about to change. GLTA

  • At a best case scenario, this company would have a drug on the market in 2 years. Since the FDA is very suspect of genetic manipulations, you can bet they'll be looking at RNAi with their finest lens.

    In the interim, we have a gap to fill at $35/share.

  • Revenues driven by recent contracts for the most advanced life saving diagnostics will expand 150 times in the next 24 months. And that is just the beginning!

    Millennium Healthcare (MHCC) recently announced newly SIGNED contracts with ACO’s IPA’s and MSO’s to provide exclusive, state-of-the-art, non-invasive cardiovascular and cancer diagnostics to 1,300 locations that will escalate Millennium’s current revenues of $2 million per year to over $300 million per year.

    Cardiovascular and cancer diagnostics rolling out to physician’s offices this year.

    Revenues will begin rapid growth by year end.

    Market size for Millennium Diagnostics is 35,000 primary care offices. The first 1,300 recently contracted with Millennium and the rest are standing in line to sign up with Millennium because:

    § Millenniums program increases physician’s revenues dramatically
    § Millennium’s diagnostics are fully paid by Medicare and are free to patients
    § Millennium’s diagnostics appeal to patients because they are life-saving, fast, painless and highly accurate
    § Millennium’s diagnostics are exclusive from Millennium only
    § The physician pays no up front capital costs

    Millennium’s market cap is under $40 million today and shares are selling at under $1.00.

    What will this growth do to the price of MHCC shares?

    Millennium HealthCare is well positioned for explosive growth that is rarely seen.

    Sentiment: Strong Buy

  • Reply to

    WHY IS THE PRICE SINKING?

    by artusaj Jun 2, 2014 9:43 AM

    There are a lot of great pipelines out there. ALNY has no drugs and works it the hardest therapeutic arena
    currently. If you can tell me what year you expect a drug to pass the FDA that Alnylam makes. then I can
    assuage your sinking feeling.

  • Reply to

    WHY IS THE PRICE SINKING?

    by artusaj Jun 2, 2014 9:43 AM

    haha. thanks for the chuckle

  • Reply to

    WHY IS THE PRICE SINKING?

    by artusaj Jun 2, 2014 9:43 AM

    Overpriced !
    No drug on the market !
    Think about it !
    Henry MD

    Sentiment: Sell

  • interesting article. "Using a miniature model of the human intestine, only a few millimeters in size and made from stem cells, the scientists deactivated a gene in the cells tied to metabolic regulation called FOXO1. Once disabled, the cells began producing insulin. " possibly up ALNYs alley?

    "The method, described today in the journal Nature Communications, raises the possibility of replacing insulin-making pancreatic beta cells lost in diabetics by using a drug to retrain patients’ existing cells. While progress has been made in generating beta cells from stem cells, the method hasn’t yet produced ones with all the needed functions, said Domenico Accili, the study’s lead author. Plus, such cells would require transplantation. "

  • MEDA targets 600 million social media users in China as growth potential increases.

  • Reply to

    ALNY and ARWR New Drug

    by danwebs2014 Jun 20, 2014 10:54 AM

    It looks like they are both partnering with Alpha-1 (it's a reasearch foundation) to address the same illness (AAT Deficiency Liver Disease) using competing delivery platforms. I suppose it could also be a combination of both delivery platforms in one study.... someone call me out if I'm wrong here.
    But it's probably competing platforms in two studies side by side, sharing a control group... otherwise why not mention some form of cooperation between the two companies in the pr's?

    From the Anylam pr:
    New data presented at The Liver Meeting are based on an AAT-targeted siRNA conjugated to an N-acetylgalactosamine (GalNAc) ligand, which is designed to achieve targeted delivery of RNAi therapeutics to hepatocytes through uptake by the asialoglycoprotein receptor. Studies were performed in transgenic mice overexpressing the human Z-AAT protein. Subcutaneous administration of a GalNAc-siRNA conjugate targeting Z-AAT led to dose-dependent knockdown of serum levels of human Z-AAT. A single dose of 3 mg/kg led to greater than 95% knockdown of Z-AAT protein that lasted for greater than two weeks. In a multi-dose experiment, twice-weekly dosing at 0.5 mg/kg led to greater than 90% knockdown.

    From the arrowhead pr:
    "ARC-AAT is designed to inhibit the production of mutant AAT protein in the liver and in preclinical studies it has shown high levels of knockdown with long duration of action. AATD patients express mutant AAT, which can accumulate in hepatocytes and damage the liver. Liver disease associated with Alpha-1 antitrypsin deficiency has no current treatment options and patients can progress to cirrhosis, hepatocellular carcinoma, and may require liver transplant." Arrowhead has developed a novel unlocked nucleobase analog (UNA)-containing RNAi molecule designed for systemic delivery using the Dynamic Polyconjugate (DPC) delivery system.

  • Does anyone have insight into why ALNY and ARWR announced trials for a drug addressing the same disease on the same day at almost the same time.

  • The possible illegal attempt of ALNY in filing patent infringement will hopefully backfire for ALNY and for MERCK. Drawing very companies into a expensive and drawn battle in the courts only helps Big Pharma( Merck) and their surrogate ALNY.

    The fact is not only is it a restraint of trade ( Anti-trust violation) but if it can proven that they knowingly knew there was no patent infringement, then ALNY and Merck will dissolve by their chicanery, if US Attorney General files papers against the two under the Rico statue , for Conspiracy

  • Reply to

    WHY IS THE PRICE SINKING?

    by artusaj Jun 2, 2014 9:43 AM

    The possible illegal attempt of ALNY in filing patent infringement will hopefully backfire for ALNY and for MERCK. Drawing very companies into a expensive and drawn battle in the courts only helps Big Pharma( Merck) and their surrogate ALNY.

    The fact is not only is it a restraint of trade ( Anti-trust violation) but if it can proven that they knowingly knew there was no patent infringement, then ALNY and Merck will dissolve by their chicanery, if US Attorney General files papers against the two under the Rico statue , for Conspiracy.

  • Reply to

    WHY IS THE PRICE SINKING?

    by artusaj Jun 2, 2014 9:43 AM

    sentiment. psychology of the market.... once big pharma/big biotech start the biotech acquisition binge the sentiment should flip very quickly. Seems like they are all content to let the dust settle in the biotech index first.... so who knows when this will begin in earnest. It will probably surprise most people when things turn but it's been painful for those of us holding this spring. Thankfully I am still sitting on a double in ALNY. I wish I could say the same for all my bios...... groan.

  • IT HAS A GREAT PIPELINE.

  • Mast Therapeutics (MSTX) See the SEC filing.

  • Reply to

    ALNY's HBV Program

    by iamidiot001 May 12, 2014 12:20 PM

    going back to 100 PPS.... low Market cap for nice risk/reward

ALNY
55.55+0.22(+0.40%)3:19 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.